SBIR/STTR Research Award
Novel Therapeutic Approach to Hypercholesterolemia Using Anti PCSK Selected Immune Repertoires
Award amount
$1,482,472Program and phase
SBIR · Phase IIAward year
2016Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- ABEOME CORPORATION
- Proposal award date
- 2016-09-19
- Contract end date
- 2018-08-31
- UEI
- GSGQJ6BDSHJ3
- Solicitation number
- PA14-071
- Topic code
- NHLBI
Research abstract
DESCRIPTION provided by applicant We have developed and completed a proof of principle on a new transgenic mouse model for comprehensive characterization of the antibody repertoire made in response to PCSK injection and have identified a set of high affinity neutralizing antibodies which will be tested in animals for efficacy and potency PUBLIC HEALTH RELEVANCE Therapeutic and diagnostic applications of monoclonal antibodies mAbs offer a way to target treatments to specific proteins However monoclonal antibodies have traditionally been made using hybridoma technologies which only access a small fraction of the immune system Abeome has developed a novel method of antibody discovery using direct sorting of antigen specific antibody producing cells Thus the immediate goal for this Phase project is to test and improve Abeomeandapos s newly discovered antibodies that neutralize the PCSK LDLR interaction in animals to determine their efficacy and potency Our ultimate goal is to develop an immuno therapeutic for the treatment of hypercholesterolemia and to partner the technology with pharmaceutical biotechnology companies
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Novel Therapeutic Approach to Hypercholesterolemia Using Next-Generation DNA Sequ
- Development of a TAVI Device with a Reduced Crossing Profile
- Development of a transgenic mouse line engineered to permit selection and cloning
- Novel Caenorhabditis Elegans Reagents
- Novel Markers on Human Embryonic Stem Cells
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- DUCTUS ARTERIOSUS STENT TO IMPROVE CONGENITAL HEART DEFECT MORTALITY
- Head Up CPR and Aortic Occlusion to Improve Survival after Refractory Cardiac Arrest
- Free-Breathing Dynamic Cardiopulmonary Function Imaging System to use with Xenon MRI
- The Next Wave of Asthma Therapeutics
- Bearingless flux reversal motor for neonatal and pediatric extracorporeal life support applications
Research funding history
6 SBIR/STTR records share this UEI (2004–2016). Reported award amounts total $2,334,449. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services